Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

24
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
24
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

54
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response...
54
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

23
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
23
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.2K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.3K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.3K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.7K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of High-Intensity Focused Ultrasound in the Periorbital Rejuvenation: A Systematic Review.

Aesthetic surgery journal. Open forum·2026
Same author

Correction: Computational Modelling of Platysma Muscle Mechanics: Challenging the Isometric Contraction Paradigm and Implications for the Treatment of Neck Bands.

Aesthetic plastic surgery·2026
Same author

Botulinum Toxin A Myths, Evidence, and Global Media Narratives.

Aesthetic plastic surgery·2026
Same author

Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.

Aesthetic plastic surgery·2026
Same author

Computational Modelling of Platysma Muscle Mechanics: Challenging the Isometric Contraction Paradigm and Implications for the Treatment of Neck Bands.

Aesthetic plastic surgery·2026
Same author

A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.

Aesthetic plastic surgery·2026

Related Experiment Video

Updated: Feb 20, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.8K

Challenging Interchangeability: Dynamic Dose-Response Modelling of Botulinum Toxin A Products.

Eqram Rahman1, Parinitha Rao2, Karim Sayed3

  • 1Research and Innovation Hub, Innovation Aesthetics, London, UK. Eqram.rahman@gmail.com.

Aesthetic Plastic Surgery
|February 18, 2026
PubMed
Summary

Dynamic dose conversion ratios for Botulinum Neurotoxin type A (BoNT-A) formulations are essential, as static ratios fail to capture pharmacodynamic variability. This study provides time-resolved dose equivalence estimates for six BoNT-A products, improving treatment precision.

Keywords:
AbobotulinumtoxinABotulinum toxin type ADaxibotulinumtoxinADose conversionGlabellar linesIn silico modellingIncobotulinumtoxinALetibotulinumtoxinAOnabotulinumtoxinAPrabotulinumtoxinA

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.6K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

9.0K

Related Experiment Videos

Last Updated: Feb 20, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.8K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.6K
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
14:10

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors

Published on: November 14, 2014

9.0K

Area of Science:

  • Pharmacology
  • Computational Biology
  • Aesthetics and Therapeutics

Background:

  • Current Botulinum Neurotoxin type A (BoNT-A) dose conversions are empirical and lack precision.
  • Significant pharmacodynamic variability exists among different BoNT-A formulations.
  • A need exists for dynamic, time-resolved dose equivalence estimates for improved clinical application.

Purpose of the Study:

  • To generate dynamic, time-resolved dose equivalence estimates for six FDA-approved BoNT-A formulations.
  • To compare the clinical performance and temporal efficacy of onabotulinumtoxinA (ONA), abobotulinumtoxinA (ABO), incobotulinumtoxinA (INCO), daxibotulinumtoxinA (DAXI), prabotulinumtoxinA (PRABO), and letibotulinumtoxinA (LETI).
  • To establish a robust framework for effect-based dose equivalence.

Main Methods:

  • Development of a hybrid, time-resolved in silico pharmacodynamic model.
  • Simulation of onset, peak effect, and decay kinetics in 10,000 virtual patients per formulation.
  • Determination of dose equivalence using Area Under the Response Curve (AURC) and time above efficacy threshold, with external validation.

Main Results:

  • Simulated durations varied from 10.6 weeks (ABO) to 14.5 weeks (PRABO).
  • Significant temporal drift in conversion ratios observed, with ABO and LETI showing increasing ratios and DAXI/PRABO showing decreasing ratios.
  • PRABO and DAXI demonstrated highest efficiency (AURC/unit), while decay rate (koff) was the primary determinant of efficacy duration.

Conclusions:

  • Static dose conversion ratios are inadequate for representing BoNT-A formulation dynamics.
  • The simulation-based approach accurately reproduces clinical outcomes and provides a reliable method for dose equivalence.
  • This data-driven framework enhances precision in product substitution and personalized treatment planning for BoNT-A therapies.